I checked earlier today and found an option for initial listing as low as $2 on the Nasdaq capital markets as well as the NYSE- AMEX
Not that it makes a big difference at this point, but I expect to see an increase in burn rate as the trial progresses, other products are pushed into trials, and commercialization prep begins. My estimates have the company funded until the end of 2014 after the warrant $ is factored in. I expect a partnership on one or two of the hydrogel products to "bridge the gap" in financing until the scaffold is commercialized and revenue generations begins. That said, I have become more open to the possibility of a market offering for an additional raise if the pps increases dramatically on the Nasdaq.
I think it depends on your timeframe Cyn. The way the stock has been moving the "I could sell now and buy back in a month at a lower price" seems to holding true and to be honest could be a self fulfilling prophecy as people race each other to follow suit. I guess the silver lining in it is that it should rush back up just as quickly with any good news.
The FDA doesn't bow to begging. If it's not effective, it's not effective. Efficacy is yet to be definitely proven or else they would have been fast-tracked.
You got it!
Nate, I'm guessing you're Nateb25 on icell? If so, my handle on there is ForTheFuture.
There are many other organizations working on treatments for chronic SCI. The future is promising, but no one has yet been able to get an immobile person mobile again. It will be years before an approved therapy is released to the public, even if NVIV is successful. I'm no PHD, but my guess is it will be a mix of different cell types used to generate the neuronal growth required. The Miami Project thinks Schwann cells are the key. I'm not convinced just yet. Regardless of who's therapy works (Miami Project, STEM, CUR, etc), NVIV is in a good position to leverage the scaffold and hydrogel tech to improve upon the cell therapy itself.
In 10 years time, the medical landscape will be completely different from what we see now due to the advancements in Regenerative medicine. Some companies will fail along the way and some will succeed. As investors, we all hope that we've found the right ones. And hope is the antithesis of depression. Good luck to all.
Thats a great point, MC. And actually, one of my other regenerative medicine investments (I won't say the name to avoid being labeled a pumper) just recently stated an interest in getting into the veterinary market. They're still in a phase I trial, but are seeing great results. Because of the less stringent regulatory thresholds, the vet market is much easier and quicker to get into. The interesting piece is going to be pricing. Because NVIV is still in the early stages of development, I think I'd rather see them license out the tech, rather than start it up themselves. I'd like them to focus on the human market, but I certainly don't want them to turn a blind eye on other sectors that could generate revenue.
Hey Buytheblood, Could you point me towards the section in the 10K you're referencing? I'm trying to get caught up on this S-3 business. Thanks in advance.
Oilup, if you're one of the younger folks, then 3k shares can be quite a bit and I applaud you taking risks in the equities market to secure your future.
Zachary, I recommend doing some due diligence on GTFO.
Get The F Out has been making their way quickly through clinical trials.
BigFella, certainly not ALL avoid the OTC. There are some that even specialize in it, however for the "Megafunds" , if you will, there are certain restrictions in their charter that prevent them from investing in stocks on the OTCBB.
CFO dot kom has a good article titled How Low Is Too Low. I recommend giving it a read.
Yes! Thanks for getting into the importance of getting on a major stock exchange. IMO, if done correctly, it can mark a new beginning for the company. This will be huge and I hope Frank has done all the necessary due diligence to seed institutional investors prior to the uplist. All the tv interviews are a drop in the bucket compared to getting the buy-in of a few fund managers.
It would seem the Geisinger pre-clinical data hasn't yet been submitted for publishing. I expect the remainder of the primate studies being published to be the next catalyst, although curiously there was no mention of it in the 10Q.
There will be a PR when the warrant call period is over though I'm not sure what the effect on the PPS will be.
Frank on the news tends to generate a small pop and then back down. Doesn't seem to last but may be good for traders.
The company would be smart to time the start of the trials with the uplisting so as to provide a catalyst of sorts as the same time they're opening up to institutional investors. I'm sure Frank has consultants he's working on to ensure a successful uplist. Unfortunately, unless that primate study gets published soon, I don't see any release from the current downward pressure. I continue to hold my shares though, as I'm focused on a period beyond the next 2 months and if the company does happen to throw out any positive surprises, I don't want to be caught out of the water.
Smart way to play it, Nate.
I'm thinking we'll see volatility for awhile longer before a steady climb in July in anticipation of the trials starting.
Amanda, yes and no.
The total is around $15/$16 million. They've already converted about $5 of it in April, so about $10M left.
The quarterly report is due next week I believe. We should see a press release soon. Hoping we see some new info to balance out the selling pressure which I'm sure is coming from former warrant holders or people selling in anticipation if warrants hitting the market. Sucks to see it in the red and it may continue for awhile, but the good news is that it's definitely for the better in the long term as the warrant conversions buy NVIV another year of operating cash. I'm sure the company would have preferred to have done a market offering at a slight discount to the market instead, but it's all part of the game and doesn't change the long-term potential of the company.
For long holders, just remember - In a few months, the price today or tomorrow won't even matter.
It was buried in the PR so you and others probably didn't see it, but when the warrants were forced to be pulled at $2.80 last week, the company also cancelled the Exchange offer. It would seem that the exchange was plan B in case the $2.80 minimum wasn't met.